Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

nsidered before initiating therapy.

About HUMIRA

In addition to its use in Crohn's disease, HUMIRA is also approved by the FDA for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA is also indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases.

To date, HUMIRA has been approved in 75 countries and more than 250,000 patients worldwide are currently being treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases.

More information about HUMIRA, including full prescribing information and Medication Guide, is available on the Web sit
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 Diseases largely eradicated in ... ago are returning. Measles was declared eliminated in 2000, ... as of August 15—the highest incidence in 20 years. ... department declared whooping cough a problem of "epidemic ... sick and dying from these preventable diseases—in part because ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... Oct. 10, 2011 IRIDEX Corporation (Nasdaq: IRIX ... named President and Chief Executive Officer effective today. Dr. Beck ... become Chief Technology Officer, and will also replace Mr. Boutacoff ... 47, has spent the majority of his career in leadership ...
... Cantel Medical Corp. (NYSE: CMN ) will ... ended July 31, 2011 on Thursday, October 13 before the ... results at 11:00 AM ET.  Participating in the call will ... CEO; Seth R. Segel, Executive Vice President; and Craig A. ...
Cached Medicine Technology:IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 2IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 3IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO 4Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 Market ... Industry, 2009-2019 is a professional and in-depth market ... The report firstly reviews the basic information of ... technology. The report then explores global and China’s ... specification, capacity, production value, and market share etc. ...
(Date:8/30/2014)... August 30, 2014 Serving contented clients ... India, Profit By Outsourcing is now offering discount ... The company gives emphasize on putting forward the best ... to clients. Their dedicated team of professionals and web ... They can handle even the critical issues of web ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... consolidated litigation for transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ... the company’s request to sever four cases selected ... to an Order issued on August 18, 2014, ... Southern District of West Virginia disagrees with Boston ...
(Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
Breaking Medicine News(10 mins):Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... System for Rapid Testing for Infectious Diseases Incorporates the ... ARBOR, Mich., May 18 BD Diagnostics, a segment ... BDX ), and HandyLab, Inc. announced today that they ... commercialize its molecular assays on a new BD MAX(TM) ...
... Payment Support Insurance Industry Corporate GreeningSAN DIEGO and ... a leading provider of medical cost containment, provider ... over 70% of U.S. automotive insurance payers, and ... and Gateway Services to Workers, Compensation, Auto Medical ...
... be presented on Abbott,s market-leading XIENCE V(R) stent- Educational ... stent in developmentBARCELONA, Spain, May 18 Abbott (NYSE: ... of major events and news announcements during EuroPCR 2009 ... presentation of new data from the SPIRIT V post-approval, ...
... and PrEP Research and Calls for Urgent Coordination and Leadership ... "It,s an exciting time in HIV prevention research. We will ... research trials this year, as well as see the start ... answers in the years to come," said Mitchell Warren, AVAC ...
... SAN DIEGOCystic fibrosis patients may benefit from a new ... mucous, which is a key factor in the disease, ... The research will be presented on Sunday, May 17, ... San Diego., "Our results suggest that we have identified ...
... help physicians solve a perennial problem: patients who don,t ... the Kaiser Permanente Center for Health Research, in Portland, ... patients with asthma to fill or refill their prescriptions ... be presented on May 17 at the 105th International ...
Cached Medicine News:Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 2Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 3Health News:BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays 4Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 2Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 3Health News:Mitchell and Jopari Say 'Green Transaction Initiatives' Play Key Role in P&C and Group Health Industry Environmental Best Practices 4Health News:Abbott Announces EuroPCR 2009 Activities 2Health News:Abbott Announces EuroPCR 2009 Activities 3Health News:Abbott Announces EuroPCR 2009 Activities 4Health News:Piecing Together the HIV Prevention Puzzle 2Health News:Piecing Together the HIV Prevention Puzzle 3Health News:Piecing Together the HIV Prevention Puzzle 4Health News:Sodium channel blocker shows promise as a potential treatment for cystic fibrosis 2Health News:Increasing ICS compliance: The voice may be recorded, but the results are real 2Health News:Increasing ICS compliance: The voice may be recorded, but the results are real 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: